A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria

American Journal of Transplantation

Volumn 8, Issue 4, 2008, Pages 839-846

  Volk, M L ^a,c   Vijan, S ^b,c   Marrero, J A ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Ethics; Hepatocellular carcinoma; Liver transplantation; Public policy

Indexed keywords

ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; CRITERION VARIABLE; GEOGRAPHICAL VARIATION (SPECIES); HEALTH HAZARD; HUMAN; LIFESPAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; ORGAN DONOR; PRIORITY JOURNAL; PROBABILITY; SURGICAL RISK;

CARCINOMA, HEPATOCELLULAR; GRAFT SURVIVAL; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LIVING DONORS; MARKOV CHAINS; NEOPLASM TRANSPLANTATION; PATIENT SELECTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TISSUE DONORS; TREATMENT OUTCOME; WAITING LISTS;

EID: 40449097658     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2007.02138.x     Document Type: Article

References (47)

1. Penn I. Hepatic transplantation for primary and metastatic cancers of the liver. Surgery 1991 110 : 726 734 discussion 34-35.
2. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996 334 : 693 699.
3. Barbara L, Benzi G, Gaiani S et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: A multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology 1992 16 : 132 137.
4. Kulik L, Abecassis M. Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology 2004 127 (5 Suppl 1 S277 S282.
5. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005 42 : 1208 1236.
6. Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer 1996 77 : 2217 2222.
7. Llovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 2002 359 : 1734 1739.
8. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: An update. Ann Intern Med 2003 139 : 817 823.
9. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: Comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 2002 8 : 765 774.
10. Roayaie S, Llovet JM. Liver transplantation for hepatocellular carcinoma: Is expansion of criteria justified Clin Liver Dis. 2005 9 : 315 328.
11. Yao FY. Expanded criteria for hepatocellular carcinoma: Down-staging with a view to liver transplantation-yes. Semin Liv Dis 2006 26 : 239 247.
12. Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA. The survival benefit of liver transplantation. Am J Transplant 2005 5 : 307 313.
13. UNOS. Policy 3.6, Organ Distribution: Allocation of Livers; revised September 18, 2007.
14. Amin MG, Wolf MP, TenBrook JA, Jr. et al. Expanded criteria donor grafts for deceased donor liver transplantation under the MELD system: A decision analysis. Liver Transpl 2004 10 : 1468 1475.
15. Roberts JP, Dykstra DM, Goodrich NP, Rush SH, Merion RM, Port FK. Geographic differences in event rates by model for end-stage liver disease score. Am J Transplant 2006 6 : 2470 2475.
16. Rodriguez-Luna H, Vargas HE, Moss A, Reddy KS, Freeman RB, Mulligan D. Regional variations in peer reviewed liver allocation under the MELD system. Am J Transplant 2005 5 : 2244 2247.
17. OPTN. 2005 Annual Report. 2005 cited December 18, 2006 Available from : http://www.optn.org/data/annualReport.asp. Accessed January 15, 2007.
18. Sarasin FP, Majno PE, Llovet JM, Bruix J, Mentha G, Hadengue A. Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective. Hepatology 2001 33 : 1073 1079.
19. Cholongitas E, Marelli L, Shusang V et al. A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation. Liver Transpl 2006 12 : 1049 1061.
20. Shechter SM, Bryce CL, Alagoz O et al. A clinically based discrete-event simulation of end-stage liver disease and the organ allocation process. Med Decis Making 2005 25 : 199 209.
21. OPTN. 2006 Annual Report. Available from : http://www.optn.org/data/ annualReport.asp.Accessed August 12, 2007.
22. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. He patology 2003 37 : 429 442.
23. Takayasu K, Arii S, Ikai I et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006 131 : 461 469.
24. Pelletier G, Ducreux M, Gay F et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: A multicenter randomized trial. Groupe CHC. J Hepatol 1998 29 : 129 134.
25. Onaca N, Davis GL, Goldstein RM, Jennings LW, Klintmalm GB. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: A report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl 2007 13 : 391 399.
26. Bravata DM, Olkin I, Barnato AE, Keeffe EB, Owens DK. Health-related quality of life after liver transplantation: A meta-analysis. Liver Transpl Surg 1999 5 : 318 331.
27. Longworth L, Bryan S. An empirical comparison of EQ-5D and SF-6D in liver transplant patients. Health Econ 2003 12 : 1061 1067.
28. Ratcliffe J, Longworth L, Young T, Bryan S, Burroughs A, Buxton M. Assessing health-related quality of life pre- and post-liver transplantation: A prospective multicenter study. Liver Transpl 2002 8 : 263 270.
29. Bryce CL, Angus DC, Switala J, Roberts MS, Tsevat J. Health status versus utilities of patients with end-stage liver disease. Qual Life Res 2004 13 : 773 782.
30. Rhodes R, Battin MP, Silvers A. Medicine and Social Justice: Essays on the Distribution of Health Care. Oxford : Oxford University Press 2002.
31. Ubel PA, Loewenstein G. Distributing scarce livers: The moral reasoning of the general public. Soc Sci Med 1996 42 : 1049 1055.
32. Smith CM, Davies DB, McBride MA. Liver transplantation in the United States: A report from the Organ Procurement and Transplantation Network. Clin Transpl 2007 : 19 30.
33. Stahl JE, Kong N, Shechter SM, Schaefer AJ, Roberts MS. A methodological framework for optimally reorganizing liver transplant regions. Med Decis Making 2005 25 : 35 46.
34. Llovet J, Ricci S, Mazzaferro V et al. Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): Results of a Phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol 2007 25 (18 Suppl 1 LBA1.
35. El-Serag HB, Siegel AB, Davila JA et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: A population-based study. J Hepatol 2006 44 : 158 166.
36. Freeman RB, Mithoefer A, Ruthazer R et al. Optimizing staging for hepatocellular carcinoma before liver transplantation: A retrospective analysis of the UNOS/OPTN database. Liver Transpl 2006 12 : 1504 1511.
37. Mas VR, Fisher RA, Archer KJ et al. Genes associated with progression and recurrence of hepatocellular carcinoma in hepatitis C patients waiting and undergoing liver transplantation: Preliminary results. Transplantation 2007 83 : 973 981.
38. Mashoi J, Puhl S, Thyagarajan V et al. Liver transplantation for hepatocellular carcinoma: Validation of the Milan criteria using the UNOS database. Hepatology 2006 44 (4 Suppl 1 407A.
39. Decaens T. What is the impact of UCSF expansion criteria according to pre-liver transplantation tumor characteristics on survival: Results from 14 French centers. Hepatology 2004 40 (4 Suppl 1 550A.
40. Roayaie S, Frischer JS, Emre SH et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 2002 235 : 533 539.
41. Duffy JP, Vardanian A, Benjamin E et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: A 22-year experience with 467 patients at UCLA. Ann Surg 2007 246 : 502 509 discussion 9-11.
42. Yao FY, Ferrell L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 2001 33 : 1394 1403.
43. Yao FY. Liver transplantation for hepatocellular carcinoma: A 5-year prospective study validating expanded criteria applied to pre-operative imaging. Hepatology 2006 44 (4 Suppl 1 191A.
44. Freeman RB, Edwards EB, Harper AM. Waiting list removal rates among patients with chronic and malignant liver diseases. Am J Transplant 2006 6 : 1416 1421.
45. Cheng SJ, Pratt DS, Freeman RB, Jr., Kaplan MM, Wong JB. Living-donor versus cadaveric liver transplantation for non-resectable small hepatocellular carcinoma and compensated cirrhosis: A decision analysis. Transplantation 2001 72 : 861 868.
46. Sharma P, Balan V, Hernandez JL et al. Liver transplantation for hepatocellular carcinoma: The MELD impact. Liver Transpl 2004 Jan 10 : 36 41.
47. Llovet JM, Bustamante J, Castells A et al. Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials. Hepatology 1999 29 : 62 67.